MedTrace Logo

Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host

NCT02891395 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2025-12-22

No results posted yet for this study

Summary

Open label non-randomized multicenter phase 2 trial with direct individual benefice

Conditions

Interventions

DRUG

Imatinib Mesylate and Nilotinib

For patients under Imatinib Mesylate: the total length of follow up period for those patients will be for 52 weeks following IM treatment, with a follow up at weeks IM4, IM8, IM12, IM26, IM38 and IM52. For patients requiring a salvage phase: after the switch for nilotinib, the total length of follow up period for this phase will be for 52 weeks following nilotinib treatment, with a follow up at weeks nilo4, nilo8, nilo12, nilo26, nilo38 and nilo52.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • YAKOUB-AGHA Ibrahim, MD · University Hospital, Lille

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-24
Primary Completion
2017-07-26
Completion
2017-07-26

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02891395 on ClinicalTrials.gov